TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Performance Evaluation of the Depth of Anesthesia Monitors in Pediatric Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* physical status classification (ASA) I - II~* general balanced anesthesia~* mechanically ventilated with laryngeal mask~Exclusion Criteria:~* severe developmental delay~* neurological disorders or receiving treatment with antiepileptic or stimulant~* patients with preexisting lung or cardiac disease~* airway abnormalities~* marked skin sensitivity and conditions where the placement of the BIS and Entropy sensor or process of assessment would interfere with the surgery procedure.~* patients receiving local anaesthesia, regional block combined with general anaesthesia~* sedation administered by non anesthesiologists for invasive and noninvasive diagnostic or therapeutic procedures

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Children age between 1 month to 12 months
- Group 2 (Type: None): Children age between 13 months and 36 months
- Group 3 (Type: None): Children age between 37 months to 144 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients with RRP which sign the informed consent form with both parts of the study will be enrolled.~Exclusion Criteria:~Patients who experience severe side effects of vaccination after the first or second dose will not be vaccinated with the third dose and they will be excluded from the study. Patients who will not receive all three doses within one year and 30 days will be also excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine Silgard (Type: EXPERIMENTAL): vaccination with tetravalent antiviral vaccine, 3 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12-month Study of AMG 073 in Renal Osteodystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age of greater~* Using effective contraceptive measures~* iPTH greater than or equal to 300 pg/mL~* Serum Calcium greater than or equal to 8.4 mg/dL; Hemoglobin greater than 9~* Stable hemodialysis for 1 month prior to day 1~Exclusion Criteria:~* Any unstable medical condition~* Pregnant or nursing women Recent parathyroidectomy~* Change in Vitamin D therapy~* Recent MI, Seizure, Malignancy, GI Disorder~* Inability to swallow tablets

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMG 073 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and female subjects;~* Body Mass Index 30-40 kg/m2;~Exclusion Criteria:~* Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Liraglutide
- Placebo (Type: PLACEBO_COMPARATOR): Placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* untreated myeloma patients~* age \>65 years of age or younger but excluded from transplant procedure~* Durie \& Salmon stage II or III myeloma and measurable disease.~* Patients agreed to use contraception~Exclusion Criteria:~* other cancer~* psychiatric disease and any grade 2 peripheral neuropathy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melanoma Perception and Health Literacy in People of Color

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English-speaking~* Self-identifies with one of the following races/ethnicities: African American, Asian/Pacific Islander, American Indian and Alaskan Native, or Hispanic~Exclusion Criteria:~* Not proficient in English~* Unable to give informed consent~* Does not self-identify with the following races/ethnicities: African American, Asian/Pacific Islander, American Indian and Alaskan Native, or Hispanic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ABCDEs of Melanoma Skin Cancer (Type: EXPERIMENTAL): A modified melanoma educational intervention that uses the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation but also incorporates the nomenclature melanoma skin cancer; indicates that melanoma is relevant for everyone regardless of race and ethnicity; includes images of melanoma on ethnic skin; informs people of the likelihood of melanoma developing in acral, subungual and mucosal surfaces; and provides guidance on self-skin examinations.
- ABCDEs of Melanoma (Type: ACTIVE_COMPARATOR): A conventional melanoma educational intervention using the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female \>= 28 years of age~* Confirmed diagnosis of cystic fibrosis~* Forced Expiratory Volume in 1 second (FEV1) \>= 40% predicted~* Clinically stable~* Ability to reproduce spirometry~* Ability to understand and sign the informed consent~Exclusion Criteria:~* Use of an investigational agent within 4-week period prior to Visit 1~* Chronic daily use of ibuprofen or other NSAIDS~* Chronic daily use of insulin,oral diabetic agents or oral hypoglycemic agents~* History of hypersensitivity to beta agonists~* History of hypersensitivity to glitazones~* Oxygen saturation\<92%~* Pregnant, breastfeeding or unwilling to practice acceptable birth control~* History of hemoptysis \>30cc per episode within 30 days prior to Visit 1~* Significant history of hepatic, cardiovascular, renal,neurologic, hematologic or peptic ulcer disease~* Serum Glutamic-Oxaloacetic Transaminase (SGOT)/(Serum Glutamic Pyruvic Transaminase (SGPT) \>3 times the upper limit of normal at screening, documented biliary cirrhosis,or portal hypertension~* Creatinine \> 1.8 mg/dL at screening~* Inability to swallow pills~* Presence or abnormality that in the opinion of the investigator would compromise the safety or the quality of the data~* Subjects who have routinely taken ibuprofen or other NSAIDS; prednisone or other systemic corticosteroids, or insulin, or oral diabetic agents within 4 weeks prior to visit 1 or who have taken these medications as needed within 72 hours prior to visit one will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pioglitazone (Type: EXPERIMENTAL): All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily Other names: Actos, Takeda

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Give their signed written informed consent to participate.~* Are at least 40 years of age and no older than 80 at Visit 1.~* A female of non-child bearing potential or child bearing potential, has a negative serum pregnancy test, and agrees to approved contraceptive methods.~* COPD Diagnosis: Subjects with an established clinical history of COPD as defined by the American Thoracic Society(ATS)/European Respiratory Society (ERS).~* Current or former smokers with a history of at least 10 pack-years of cigarette smoking.~* FEV1/FVC ratio of \<0.70.~* Post-bronchodilator FEV1 must be ≥ 30% and \<80% predicted normal value calculated using the Third National Health and Nutrition Examination Survey (NHANES III) reference equations, and must also be greater than or equal to 750 mL.~* Subject is willing and, in the opinion of the Investigator, able to adjust current COPD therapy as required by the protocol.~Exclusion Criteria:~* Pregnancy, nursing females or subjects trying to conceive.~* Clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study.~* Current primary diagnosis of asthma.~* History of ECG abnormalities.~* Poorly controlled or worsening COPD prior to Screening or during the Screening Period.~* Clinically significant bladder neck obstruction or urinary retention.~* Male subjects with a trans-urethral resection of prostate (TURP) or full resection of the prostate within 6 months prior to Screening.~* Cancer that has not been in complete remission for at least five years.~* Inadequately treated glaucoma.~* History of allergic reaction or hypersensitivity to any component of the formulations used in this study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (Type: EXPERIMENTAL): Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler (GFF MDI), PT003

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The MOM Program: 5 Year Follow-up Study of a Home Visiting Program at The Children's Hospital of Philadelphia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Previous enrollment in The MOM Program; child age of 5 years (plus or minus 3 months); willingness to come to office for follow-up assessment visit; parental consent and child assent.~Exclusion Criteria: None.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- Home visiting Intervention (Type: EXPERIMENTAL): Home visiting intervention group.
- Control (Type: PLACEBO_COMPARATOR): Control condition did not receive any services.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. Patient with a primary diagnosis of IPF (according to the 2000 American Thoracic Society/European Respiratory Society (ATS/ERS) criteria, who are willing to continue trial medication.~2. Written informed consent signed prior to entry into the study, in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local law~3. Completion of 1199.30 study and still under treatment (i.e. not discontinued in parent trial)~Exclusion criteria:~1. Any disease that may put the patient at risk when participating in this trial. Reconsider carefully all exclusion criteria of trial 1199.30. However, patients may qualify for participation even though exclusion criteria may have been met during the course of participation in 1199.30, if the investigator's benefit-risk assessment remains favourable.~2. Participation in another experimental clinical trial (except 1199.30) in the last 8 weeks.~3. Women who are breast feeding or of child bearing potential not using a highly effective method of birth control for at least one month prior to inclusion and at least 10 weeks after end of active therapy.~   Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1 % per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some Intra Uterine Devices (IUDs), sexual abstinence or vasectomized partner. Female patients will be considered of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years.~4. Sexually active males not committing to using condoms during the course of the study and at least 10 weeks after the end of active therapy (except if their partner is not of childbearing potential).~5. Patients who require full-dose anticoagulation (e.g. vitamin K antagonists, heparin, hirudin etc).~6. Patients who require full-dose antiplatelet (e.g. acetyl salicylic acid, clopidogrel etc) therapy.~7. Known or suspected active alcohol or drug abuse.~8. Patient not compliant in previous trial, with trial medication or trial visits.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIBF 1120 low qd (Type: EXPERIMENTAL): Low dose BIBF 1120 once daily
- BIBF 1120 low bid (Type: EXPERIMENTAL): Low dose BIBF 1120 twice daily
- BIBF 1120 medium bid (Type: EXPERIMENTAL): Intermediate dose BIBF 1120 twice daily
- BIBF 1120 high bid (Type: EXPERIMENTAL): High dose BIBF 1120 twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Gentamicin Lavage of the Axillary Surgical Bed After Lymph Node Dissection on Drainage Discharge Volume

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of mammary neoplasms and plans to undergo an elective ALND of Berg´s levels I and II due to axillary metastasis determined preoperatively by core biopsy or evidence of metastasis in the SLNB in the intraoperative or in the differed analysis.~Exclusion Criteria:~* chronic renal failure due to possible toxicity of gentamicin~* patients undergoing a modified radical mastectomy.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Gentamicin lavage (Type: EXPERIMENTAL): Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
- Normal saline lavage (Type: ACTIVE_COMPARATOR): Patients undergoing 2 axillary lavages with 500ml of normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Less than 5 years of age at the time of the first study drug infusion~* Documented clinical diagnosis of MPS IVA based on clinical signs and symptoms of MPS IVA and documented reduced fibroblast or leukocyte GALNS enzyme activity or genetic testing confirming diagnosis of MPS IVA~* Written informed consent provided by parent or legally authorized representative after the nature of the study has been explained and prior to any research-related procedures.~Exclusion Criteria:~* Previous hematopoietic stem cell transplant (HSCT).~* Previous treatment with BMN 110.~* Known hypersensitivity to any of the components of BMN 110.~* Major surgery within 3 months prior to stuy entry or planned major surgery during the 52-week treatment period.~* Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.~* Concurrent disease or condition, including but not limited to symptomatic cervical spine instability, clinically significant spinal cord compression, or severe cardiac disease that would interfere with study participation or safety as determined by the Investigator.~* Any condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- BMN 110 Weekly (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infertility due to tubal factor and/or male factor~* Age between 20 and 35 years with regular menstrual cycles of 21-35 days~* First or second cycle in the present series of ART~* BMI (body mass index) ≥ 18 ≤ 30 kg/m2~* Basal FSH (follicle stimulating hormone) \< 10 IU/L (cycle day 2-5)~* E2 (estradiol) levels \< 50pg/mL (cycle day 2)~* AMH (anti-mullerian hormone) ≥ 1.0 ng/ml~* Antral follicle ≥ 4 to ≤ 15 follicles (both ovaries)~* Presence of both ovaries and normal uterine cavity~* Informed consent~Exclusion Criteria:~* Presence of pregnancy~* Hypersensitivity to follitropin alfa~* Ovarian cysts~* History of ≥2 succeeding ART (assisted reproductive technology) cycles IVF (in vitro fertilization) and/or ICSI (Intracytoplasmic sperm injection) before the study cycle~* Previous history of severe ovarian hyperstimulation syndrome~* Presence of polycystic ovaries (PCO)~* Presence of endometriosis and hydrosalpinx~* Presence of uterine disorders~* History of poor (\< 4 oocytes) or hyper (\> 25 oocytes) responses to FSH treatment at dose 150 IU and GnRH-antagonist (gonadotropin-releasing hormone) protocol~* Premature ovarian failure~* Ectopic pregnancy (3 month before the study cycle)~* Presence of clinically significant systemic disease~* Presence of chronic cardiovascular, hepatic, renal or pulmonary disease~* Presence of endocrine disorder~* Neoplasia~* Male infertility without mobile spermatozoa in the ejaculate, that need MESA (Microsurgical epididymal sperm aspiration)/TESE (testicular sperm extraction)/TESA (testicular sperm aspiration)~* Smoking \> 10 cigarettes/day~* Narcomania, alcoholism~* Planned PGS (preimplantation genetic screeneing) /PGD (preimplantation genetic diagnosis)

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Primapur (Follitropin alfa) (Type: EXPERIMENTAL): None
- Gonal-f (Follitropin alfa) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hypercholesterolemic patients~Exclusion Criteria:~* Patients receiving lipid-lowering agents~* Familial hypercholesterolemia~* Renal disease~* Diseases of liver, gallbladder and bile ducts~* Pregnant women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete